Abstract
The increasing prevalence of antimicrobial resistance has become a global health problem. Acinetobacter baumannii is an important nosocomial pathogen due to its capacity to persist in the hospital environment. It has a high mortality rate and few treatment options. Antibiotic combinations can help to fight multi-drug resistant (MDR) bacterial infections, but they are rarely used in the clinics and mostly unexplored. The interaction between bacteriostatic and bactericidal antibiotics are mostly reported as antagonism based on the results obtained in the susceptible model laboratory strain Escherichia coli. However, in the present study, we report a synergistic interaction between nalidixic acid and tetracycline against clinical multi-drug resistant A. baumannii and E. coli. Here we provide mechanistic insight into this dichotomy. The synergistic combination was studied by checkerboard assay and time-kill curve analysis. We also elucidate the mechanism behind this synergy using several techniques such as fluorescence spectroscopy, flow cytometry, fluorescence microscopy, morphometric analysis, and real-time polymerase chain reaction. Nalidixic acid and tetracycline combination displayed synergy against most of the MDR clinical isolates of A. baumannii and E. coli but not against susceptible isolates. Finally, we demonstrate that this combination is also effective in vivo in an A. baumannii/Caenorhabditis elegans infection model (pā<ā0.001)
Similar content being viewed by others
Introduction
The spread of antibiotic resistance is a serious threat to modern medicine. The continuing rise of antibiotic resistance in nosocomial pathogens is a grave public health concern. Acinetobacter baumannii is one of the major causes of hospital-acquired infections worldwide. The World Health Organization (WHO) has declared it as one of the most serious pathogens and is included in priority 1: ācritical groupā in the global priority pathogens list1. It is estimated that Acinetobacter spp. infects 600,000 to 1,400,000 people globally per year2. The remarkable ability of this pathogen to acquire resistance to almost all currently used antibiotics, including carbapenems, makes the situation even worse. The extreme drug resistance phenotype of A. baumannii shows a mortality rate of 70% in some cases2. The treatment options available against this pathogen are shrinking faster than the discovery rate of new antibacterials. Combining antibiotics is a promising strategy for increasing treatment efficacy and for controlling resistance evolution3,4. Despite their growing biomedical importance, fundamental questions about drug interactions remain unanswered. Especially, little is known about the underlying mechanisms of most antibiotic interactions5,6. Characterization of the underlying mechanisms of antibiotic interactions is important. The fundamental antibioticsā modes of action and pharmacodynamics alone cannot elucidate drug interactions in a simple, straightforward way. Drug interactions can be caused by relatively simple uptake effects; e.g., synergism results if one drug increases the permeability of the cell envelope to another drug4,7,8.
Antibiotic combinations have several benefits such as broadening the antibiotic spectrum and reduced toxicity, but slowing the evolution of drug resistance is a key motivation for using drug combinations9. Typically, several independent mutations are required to become resistant to a combination of drugs with different cellular targets5. Identification of drug interactions is important, because drugs may interact differently in different resistant mutants, i.e., acquired drug resistance affects the interactions between two antibiotics observed initially in wild-type drug-sensitive cells. Most of the existing knowledge about antibiotic interactions only represents data from large screening sets conducted in Escherichia coli (model laboratory strain) rather than multidrug-resistant (MDR) isolates. Further, the results point out towards antagonism between bacteriostatic and bactericidal antibiotics10,11,12. Few studies on drug interaction have been conducted in MDR isolates that showed positive drug interaction, i.e., synergism between bacteriostatic and bactericidal antibiotics13,14.
However, here we present a study describing the identification of a synergistic combination of nalidixic acid and tetracycline against MDR A. baumannii AYE (an epidemic strain in France). We extended our investigation of this synergistic combination against clinical isolates of A. baumannii and other human pathogens, including MDR E. coli (a WHO priority pathogen), and finally demonstrated the in vivo efficacy of this synergy using Caenorhabditis elegans infection model; our results highlight the dichotomy about antibiotic interactions. In addition, the underlying mechanism of this antibiotic interaction was explored using several different experimental approaches. The previous reports of antagonism between DNA synthesis inhibitors and translation inhibitors in E. coli do not seem to be universal for all other species.
Results
Screening of antibioticāantibiotic combinations identify nalidixic acid and tetracycline synergism against A. baumannii AYE
In this screening, two antibiotics, nalidixic acid and ciprofloxacin (Quinolones), were probed against antibiotics from different classes representing major classes of antibiotics such as ampicillin (Ī²-lactams), fosfomycin (Phosphonates), gentamicin (Aminoglycosides), erythromycin (Macrolides), polymyxin B (Polymyxins), tetracycline (Tetracyclines), and rifampicin (Ansamycins) against MDR A. baumannii AYE (an epidemic strain in France)15. Antibiotic interaction was studied using a two-dimensional checkerboard assay to identify the synergistic combinations. This screening identified one potent combination, i.e., nalidixic acid and tetracycline showing a Fractional Inhibitory Concentration Index (FICI) value of 0.25. Isobologram showed a synergistic growth inhibition pattern of A. baumannii AYE (Fig.Ā 1a). Most of the antibioticāantibiotic interactions displayed no interaction. The results of this screening are shown in Supplementary Fig.Ā 1 and Supplementary TablesĀ 1 and 2. Next, we performed a time-kill curve of A. baumannii AYE exposed to nalidixic acid (at 512āmg/L), tetracycline (at 64āmg/L) alone or in combination (1Ć fractional inhibitory concentration (FIC) represents nalidixic acid and tetracycline at 64 and 8āmg/L, respectively; 2Ć FIC represents nalidixic acid and tetracycline at 128 and 16āmg/L, respectively). The time-kill kinetics also showed a synergistic pattern of killing at 1Ć FIC. This combination showed a colony forming unit (CFU) log reduction up to 2 log10 and 6 log10 at 1Ć FIC and 2Ć FIC, respectively, within 6āh (Fig.Ā 1b). Nalidixic acid and tetracycline alone, even at higher concentrations, i.e., 1Ć minimum inhibitory concentration (MIC), were not able to decrease CFU counts significantly. Next, we also tested antibiotic interactions between other members of the quinolone and tetracycline classes. We selected nalidixic acid, ofloxacin, levofloxacin, and norfloxacin from the quinolone class and tetracycline, doxycycline, minocycline, and tigecycline from the tetracycline class. Most of these interactions displayed no interaction, except nalidixic acid and doxycycline, which displayed synergy with an FICI of 0.256 (Fig.Ā 1c).
The synergistic combination of nalidixic acid and tetracycline also works against MDR clinical strains of A. baumannii and E. coli
Next, we tested the synergistic combination of nalidixic acid and tetracycline against 16 MDR clinical strains of A. baumannii (all strains resistant to last-resort antibiotics including meropenem, amikacin, gentamicin, ciprofloxacin, and Co-trimoxazole). We also tested this combination against a panel of WHO priority pathogens such as E. coli, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and some other human pathogens such as Mycobacterium smegmatis, Shigella flexneri, and Salmonella enterica subsp. enterica serovar Choleraesuis. The FICI data of these clinical strains are summarized in Supplementary TableĀ 3. This synergy worked not only in the reference strain (i.e., A. baumannii AYE) but also against MDR clinical isolates of A. baumannii and E. coli (Fig.Ā 1d). The combination works synergistically in quinolone-resistant clinical strains of A. baumannii (nā=ā16) (FICI range 0.1875ā0.5 for 12 and 0.5ā0.75 for 4 strains) and E. coli (nā=ā3) (FICI range 0.25ā0.5) but not in quinolone-sensitive E. coli MG1655. When we tested the synergistic combination of nalidixic acid and doxycycline against clinical strains of A. baumannii and E. coli, it showed synergy against only six clinical strains and, hence, we did not proceed further with this combination (results are summarized in Supplementary Fig.Ā 2 and Supplementary TableĀ 4).
Identification of the mechanism of synergy between nalidixic acid and tetracycline: nalidixic acid facilitates the entry of tetracycline inside A. baumannii AYE cells
The synergy between two compounds can be due to enhanced uptake of one by another partner; synergy on the basis of enhanced uptake has been proven in earlier studies8,16. Tetracycline is a fluorescent molecule and the fluorescence of tetracycline is enhanced when it enters inside the bacterial cells. To elucidate the mechanism of synergy of nalidixic acid and tetracycline, tetracycline uptake assay was performed. Here, nalidixic acid caused a concentration-dependent increase (ranging from 1Ć MIC to 8Ć MIC) in the uptake of tetracycline (as evident by an increase in fluorescence) (Fig.Ā 2a), indicating that nalidixic acid helps tetracycline to get inside the A. baumannii AYE cells. In a similar set of experiments, tetracycline uptake assay was performed with clinical strain of E. coli (E. coli RPTU54, an MDR strain), A. baumannii SDF, and E. coli MG1655 (both strains are susceptible to nalidixic acid). An increasing concentration of nalidixic acid (ranging from 1Ć MIC to 8Ć MIC) did not change the relative fluorescence of tetracycline in the susceptible strains A. baumannii SDF and E. coli MG1655, whereas it showed enhanced uptake in MDR E. coli RPTU54 (Supplementary Fig.Ā 3), indicating that nalidixic acid (at lower concentration) does not enhance uptake of tetracycline in susceptible bacteria. We also tested whether other quinolones such as ciprofloxacin can also enhance tetracycline uptake. We found that increasing concentration of ciprofloxacin did not result in enhanced fluorescence of tetracycline (Supplementary Fig.Ā 4). This may explain why nalidixic acid displayed synergy with tetracycline, while ciprofloxacin did not.
Next, we tested whether the presence of nalidixic acid is affecting tetracycline transporters in A. baumannii AYE. Tetracycline gets inside the bacterial cell via outer membrane proteins (OMPs). Omp33 is a major OMP in A. baumannii AYE. Hence, we tested the expression level of omp33 after nalidixic acid treatment. We found that nalidixic acid enhanced the relative expression of omp33 up to twofold in A. baumannii AYE (Fig.Ā 2c). Similarly, Many MDR strains such as A. baumannii AYE efflux out tetracycline by efflux pumps. Hence, we also tested the effect of nalidixic acid on the expression of two important efflux pumps that are responsible for tetracycline efflux, i.e., AdeB and Tet(A). We found that nalidixic acid caused a downregulation in the expression of both efflux pumps, i.e., adeB and tet(A) by ~21 and ~2-fold, respectively, (Fig.Ā 2c). Enhanced uptake and reduced efflux of tetracycline by nalidixic acid may partially explain the basis of synergy between these two partners.
Assessment of membrane damage in A. baumannii AYE
Surprised with our previous result of direct enhanced uptake of tetracycline by nalidixic acid, next we investigated the mode of action of this synergy using several assays for membrane integrity such as direct measurement of membrane damage and dissipation of proton motive force (PMF). To study whether tetracycline uptake induced by nalidixic acid is due to direct membrane disruption in A. baumannii AYE, we performed membrane permeability assay induced by nalidixic acid using a membrane-impermeable dye SYTOXā¢ Orange. SYTOXā¢ Orange can only enter the cells with a compromised membrane. Flow cytometry histograms of A. baumannii AYE cells treated with nalidixic acid displayed a shift to higher fluorescence intensities indicative of membrane disruption. Histogram of A. baumannii AYE cells treated with 1Ć MIC (512āmg/L) of nalidixic acid showed extensive membrane damage (55% cells displayed shift) (Fig.Ā 3a). Tetracycline did not cause any fluorescence shift (ā¤1% cells displayed shift), indicating no role in membrane damage. The combination also displayed a similar shift (Fig.Ā 3a), as was observed in A. baumannii AYE cells treated with nalidixic acid, indicating the possible role of membrane damage behind this synergy. Next, we also tested membrane damage assay with E. coli RPTU54, an MDR clinical strain of E. coli (nalidixic acid and tetracycline displayed synergy in this strain), and we found that nalidixic acid displayed a fluorescence shift (Supplementary Fig.Ā 5), indicating that this membrane-damaging property of nalidixic acid at higher concentration might be conserved for all species. That is why, when we tested this on susceptible strains such as A. baumannii SDF and E. coli MG1655, nalidixic acid did not show any fluorescence shift, indicating no membrane damage at lower concentrations (Supplementary Fig.Ā 5).
Next, we also performed a doseāresponse assay to check whether membrane damage by nalidixic acid is a concentration-dependent phenomenon. We used membrane-impermeable dye SYTOXā¢ Orange for this assay and, interestingly, we found that nalidixic acid caused dose-dependent membrane damage in A. baumannii AYE. The EC50 (effective concentration for 50% membrane damage) for membrane damage against A. baumannii AYE cells was 158.7āĀ±ā33.2āĀµg/ml (for an OD readings at 600ānm (OD600nm)ā~ā0.3 cells) (Fig.Ā 3b). Overall, nalidixic acid displayed concentration-dependent membrane damage.
Evaluating the role of PMF on nalidixic acid and tetracycline synergy
PMF is critical for bacteria survival and it may play a central role in showing synergy between two antibacterials as shown in the previous study17. PMF of a cell is composed of two components, i.e., transmembrane electric potential (ĪĪØ) and proton gradient (ĪpH). The two components of the PMF, ĪĪØ and ĪpH, are interdependent. Intentionally controlling ĪĪØ and ĪpH through chemical combinations leads to synergy17. The PMF controls many constitutively expressed MDR efflux pumps, which provide bacteria with a first-line resistance against antibiotics18. To decipher the role of PMF-based efflux pumps in nalidixic acid and tetracycline synergy in A. baumannii AYE, a proton uncoupler, carbonyl cyanide m-chlorophenyl hydrazone (CCCP), was used. CCCP equilibrates both the transmembrane ĪpH and the transmembrane ĪĻ, and thus depletes PMF. The increasing concentration of CCCP (0, 5, 10, 15, 20, 25āĀµM) did not change the FICI of nalidixic acid and tetracycline combination, although the individual MICs changed (up to fourfold), indicating a possible role of efflux pumps in resistance of both antibiotics in A. baumannii AYE (Supplementary Fig.Ā 6). In another set of experiments, direct measurement of PMF (ĪĪØ) was performed using a fluorescent dye, Bis-(1,3-dibutylbarbituric acid)-trimethine oxonol [DiBAC4(3)]. The fluorescence of DiBAC4(3) changed in response to fluctuation in membrane potential. Fluorescence spectroscopy of DiBAC4(3) with respect to the addition of nalidixic acid, tetracycline, or its combination to A. baumannii AYE cells indicates that these two antibiotics are not involved directly in disrupting the membrane potential (Supplementary Fig.Ā 7). In summary, these two experiments suggested that nalidixic acid and tetracycline synergy does not depend on PMF in A. baumannii AYE.
Assessing the role of ROS in nalidixic acid and tetracycline synergy in A. baumannii AYE
Antibiotics are known to cause generation of reactive oxygen species (ROS) that affect many cellular targets19,20. Hence, nalidixic acid, tetracycline, and its combination were tested for the generation of ROS to check whether the synergy is ROS dependent or not. 2ā²,7ā²-Dichlorofluorescein diacetate is an oxidative sensitive dye; after intracellular de-esterification followed by oxidation, it turns to highly fluorescent 2ā²,7ā²-dichlorofluorescein. Addition of nalidixic acid (1Ć MIC, 512āmg/L), tetracycline (1Ć MIC, 64āmg/L), or both antibiotics in combination (nalidixic acid and tetracycline at 1Ć MIC of both) led to the generation of an equal amount of ROS (Supplementary Fig.Ā 8). Hence, the synergy of nalidixic acid and tetracycline cannot be explained on the basis of enhanced ROS generation in A. baumannii AYE.
Nalidixic acid and tetracycline combination shows inter-species and strain-specific cell length heterogeneity
It is well documented that DNA damage in bacterial cells leads to cellular elongation21. The antagonism between bactericidal antibiotics such as nalidixic acid and bacteriostatic antibiotics such as tetracycline has been shown in previous studies12,22. In our study, A. baumannii AYE cells did not elongate or elongate marginally under nalidixic acid stress, whereas the nalidixic acid-susceptible population of E. coli MG1655 cells elongates several times of its original length (up to 50 times) (Fig.Ā 4). E. coli RPTU54, a nalidixic acid-resistant strain, showed mixed phenotype, i.e., both normal cells and elongated cells were seen, but there was a remarkable difference in elongation between nalidixic acid-susceptible (greater elongation) and -resistant E. coli (lesser elongation) (Fig.Ā 4). The morphometric analysis of individual cells (nāāā100 cells minimum) is shown as bean plots (Fig.Ā 4). In summary, we observed a correlation between the type of antibiotic interaction and the level of antibiotic resistance.
Role of mean total protein per cell and 16s rRNA gene expression in cell length heterogeneity caused by nalidixic acid and tetracycline combination
Mean total protein increases in the presence of DNA synthesis inhibitors and this increase is caused by excessive production of ribosomes in the E. coli MG1655 cells22. The ribosome is a core part of protein synthesis machinery in a bacterial cell and total protein in a cell correlates with the ribosome. Ribosomes are composed of three species of ribosomal RNA (rRNA) (16S, 23S, and 5S rRNA)23. Mean total protein of E. coli MG1655 susceptible to nalidixic acid increased up to approximately eight times when they were treated with nalidixic acid or with a combination of nalidixic acid and tetracycline, whereas mean total protein of A. baumannii AYE and E. coli RPTU54 resistant to nalidixic acid increased only up to approcimately two to three times as compared to untreated cells (Fig.Ā 5a). Treatment with tetracycline reduced or did not change the mean total protein in A. baumannii AYE and E. coli RPTU54 cells.
Expression of 16s rRNA corroborated with our mean total protein data in these three bacterial cells. Expression of 16s rRNA of E. coli MG1655 susceptible to nalidixic acid increased by ~10- to 16-fold when they were treated with nalidixic acid, whereas expression of 16s rRNA of A. baumannii AYE and E. coli RPTU54 resistant to nalidixic acid increased only by ~2- to 4-fold, respectively (Fig.Ā 5b). Overall, there is a remarkable difference in cell lengths between quinolone-susceptible E. coli MG1655 and quinolone-resistant E. coli RPTU54 or A. baumannii AYE. Cell length of quinolone-susceptible E. coli increased many folds after nalidixic acid treatment (either alone or in combination with tetracycline), whereas quinolone-resistant E. coli did not show such an increase. Our data showed, there is a correlation between cell length and mean total protein per cell that is controlled by 16s rRNA pool. It also showed a correlation between cell length and type of antibiotic interaction between nalidixic acid and tetracycline, i.e., synergy or no interaction. Bacteria that can increase cell length under stress (treatment with either nalidixic acid alone or in combination with tetracycline) showed no interaction type, whereas bacteria that cannot increase cell length showed synergistic drug interaction.
Elucidating the role of efflux pumps in nalidixic acid and tetracycline synergy
Bacterial MDR efflux pumps are an important mechanism of antibiotic resistance. Cells with greater expression of an efflux pump will be less susceptible to various antimicrobials than its comparator with lower efflux pump expression. In our study, we compared the difference in activity level of efflux pumps at basal level between nalidixic acid-susceptible strains such as A. baumannii SDF and E. coli MG1655 with resistant strains such as A. baumannii AYE and E. coli RPTU54 using accumulation and efflux kinetics of ethidium bromide. A. baumannii AYE and E. coli RPTU54 cells effluxed out higher amount of ethidium bromide and accumulated reduced amount of ethidium bromide as compared to A. baumannii SDF and E. coli MG1655, respectively (~5.8 times higher efflux in A. baumannii AYE vs. A. baumannii SDF; similarly, ~2.8 times higher efflux in E. coli RPTU54 vs. E. coli MG1655, pā<ā0.05, Fig.Ā 6). This assay demonstrated that resistant strains have enhanced activity of efflux pumps at basal level as compared to susceptible strains.
Next, we also performed efflux inhibition assay with two commonly used efflux substrates (indicator dyes), i.e., ethidium bromide and Hoechst 33342. Our efflux kinetics data showed that nalidixic acid caused a concentration-dependent efflux inhibition of both of these dyes (Fig.Ā 2b and Supplementary Fig.Ā 9). Efflux inhibition by nalidixic acid in A. baumannii AYE cells might be responsible for reduced efflux of tetracycline that leads to cell death. As resistant bacteria rely heavily on efflux pumps as a defense mechanism against multiple antibiotics, consequently, the effect of inhibition of these pumps would be high. Overall, enhanced uptake (as previously shown) and reduced efflux of tetracycline by nalidixic acid may partially explain the basis of synergy between these two antibiotics.
In vivo efficacy of nalidixic acid and tetracycline combination in C. elegans
Finally, we evaluated the in vivo efficacy of nalidixic acid and tetracycline synergy using an established C. elegansāA. baumannii infection model. As previously reported, A. baumannii is pathogenic and lethal to the model host organism C. elegans, and this model was used to screen novel antibacterials24. The administration of nalidixic acid at 1Ć MIC (512āmg/L) did not protect the larvae against virulent A. baumannii AB5075-UW infection but tetracycline at 1Ć MIC (0.5āmg/L) protected 50% of the larvae (AB5075-UW is susceptible to tetracycline). In contrast, the combination of nalidixic acid and tetracycline prolonged their survival in a dose-dependent manner. More specifically, 60% and 50% of the larvae survived the lethal challenge for 120āh when supplemented with a combination of nalidixic acid and tetracycline at 2Ć FIC and 1Ć FIC (here FICI is 0.5), respectively (pā<ā0.001) (Fig.Ā 7), demonstrating synergistic protection of larvae in vivo against highly virulent A. baumannii AB5075-UW infection.
Discussion
Two antibiotics can interact quite differently depending on whether they are applied to drug-resistant mutants or drug-sensitive cells. In the current study, nalidixic acid and tetracycline was identified as a synergistic combination against A. baumannii AYE. Several studies have reported the antagonistic interactions between DNA synthesis inhibitors such as nalidixic acid and protein synthesis inhibitors such as tetracycline4,11,12,22. A recent high-throughput screening of pairwise drug interaction revealed the dichotomy about synergy and antagonism10. The study concluded that despite phylogenetic relatedness between E. coli, S. enterica serovar Typhimurium, and P. aeruginosa, only 30% of drugādrug interactions were common in these three species and rest of the 70% interactions were species-specific. In addition, 20% of them showed strain specificity10. Systematic exploration of drug interaction networks between 20 antibiotics representing the main modes of action in E. coli revealed that drug interactions occur frequently, but they are only partly predictable12. The results of our study also showed a similar pattern; most of the interactions were either indifferent or antagonistic. Moreover, the synergy between nalidixic acid and tetracycline, and not between ciprofloxacin and tetracycline highlights non-uniform class behavior, and it may be due to different chemical properties of the class members, and thus different dependencies on uptake and efflux systems12. Interactions between bactericidal and bacteriostatic antibiotics (which only inhibit growth) were long hypothesized to be predominantly antagonistic, as killing by bactericidal antibiotics often requires cell growth, which is prevented by bacteriostatic drugs. This view was validated in a recent study, which found that antagonistic interactions are significantly higher for bacteriostaticābactericidal pairs among all pairwise combinations of 20 antibiotics7,12. However, one recent study reported synergy between bactericidal (enrofloxacin) and bacteriostatic (tigecycline) antibiotic against tetracycline-resistant E. coli, although the study did not focus on the mechanism of synergy25.
Our study has highlighted some key findings of nalidixic acid and tetracycline synergy against A. baumannii AYE. We found that the synergistic combination of nalidixic acid and tetracycline does not depend on PMF and ROS directly, although these two factors may contribute significantly for any given synergy17,26. Reduced PMF, in turn, impairs the function of multidrug efflux pumps that use PMF to export antibiotics from the cell, causing increased sensitivity to antibiotics27. In our study also, we observed a decrease in MIC of nalidixic acid and tetracycline in A. baumannii AYE upon treatment with increasing concentration of CCCP (a proton pump inhibitor) but there was no change in FICI. However, the membrane-damaging assay highlighted a potential role of nalidixic acid in membrane damage. Tetracycline uptake assay also pointed out the role of nalidixic acid in increasing intracellular concentration of tetracycline in A. baumannii AYE cells. This result correlates with the bioavailability model, which suggests that two drugs will be synergistic if one antibiotic helps another antibioticās availability in bacterial cells, either by increasing the second drugās entry to the cell or by decreasing the second drugās degradation or efflux10,28.
Morphometric analysis of cell length distribution under nalidixic acid and tetracycline stress revealed intra-species differences in antibiotic interaction. The combination of nalidixic acid and tetracycline acted antagonistically in E. coli MG1655 (susceptible to both antibiotics), whereas this combination acted synergistically in E. coli RPTU54 (resistant to both antibiotics). Our results corroborate a previous study showing that drug interactions may vary in resistant mutants29. Just a few mutations conferring resistance to one antibiotic can entirely change the cellās response and interactions to other drugs. This raises the question as to what extent drug interactions are conserved in mutants and across microbial species. Although these principles need to be validated more broadly, they could play a key role in the future design of potent antibiotic combinations5. Antibiotic concentration is an important factor in controlling drug interactions. Multidrug efflux pumps control drug concentrations for bacterial cells. Our study highlighted the difference in the basal level activity of efflux pumps between drug-susceptible bacteria such as A. baumannii SDF and E. coli MG1655, and MDR A. baumannii AYE and E. coli RPTU54. Assessing in vitro drug interactions across a wide range of concentrations can guide in vivo studies, where variables such as absorption rates, elimination rates, and dosing regimens may lead to fluctuations in concentrations30. In our in vivo efficacy study also, combinations displayed synergistic activity by increasing the survival rates of C. elegans during infection.
Pharmacokinetics (PK) properties of nalidixic acid suggest that it can be dosed at very high concentrations. Nalidixic acid can be dosed at 4āg/day. Peak serum concentration of nalidixic acid is about 40āmg/L; however, peak urine concentration is about 150ā200āmg/L after 1āg oral administration. In addition, active metabolism of nalidixic acid leads to generation of many metabolites. Unchanged nalidixic acid appears in the urine along with an active metabolite, hydroxynalidixic acid, which has antibacterial activity similar to that of nalidixic acid. Plasma concentration (100āmg/L) has been reported for hydroxynalidixic acid31,32. These concentrations are well above the concentrations required to kill pathogens such as A. baumannii AYE. The maximum serum drug concentrations (Cmax) of tetracycline after oral and intravenous dose is around 4āmg/L. However, we can achieve a high concentration of tetracycline in urine. Previous study has shown that administration of 1āg of tetracycline in a person with a normal renal function would excrete 60% for tetracycline in the urine. Assuming an output of urine of 1.5āl/day, maximal urinary levels would be 400āmg/L33. This concentration is quite high and is well above the concentration required to kill pathogens such as A. baumannii AYE. In addition, we may achieve high drug concentration if we are using antibiotic combination through nebulization for lung infection without systemic toxicity. Recently, we have shown that doxycycline along with polymyxin B could be used to treat acute pneumonia caused by MDR (doxycycline resistant) P. aeruginosa using a nebulizer in a mouse pneumonia model34. Overall, nalidixic acid and tetracycline combination may be used to treat urinary tract infections, lung infections, and skin infections caused by Gram-negative MDR pathogens such as A. baumannii and E. coli. As our in vitro cytotoxicity data suggest, the combination of nalidixic acid and tetracycline is non-toxic even at very high concentrations (IC50āā„ā1024ā+ā256āmg/L, respectively (Supplementary Fig.Ā 10).
However, there are some limitations of the current study. First, the current study did not look at PK properties of this combination, as PK properties play a central role in therapy; future studies may investigate the in vivo PK parameters of this synergy. Second, we found variation in type of drug interaction within a single antibiotic class, but our study has not investigated the reason for such variation in detail. It will be interesting to investigate the underlying molecular mechanisms, which may aid to identify novel synergistic partners in future. Third, this study typically focuses on one or a few bacterial representative strains of A. baumannii and E. coli; in future, we would like to validate our observations on other WHO priority pathogens.
Overall, our study highlighted the potential use of this combination for narrow-spectrum therapy, because it may prevent collateral damage to other beneficial pathogens35,36,37. Meanwhile, the identification of nalidixic acid and tetracycline combination encourages us to discover more candidates systematically as potential synergistic partners and antibiotic interaction studies represent a promising strategy to tackle the multiple drug-resistant bacterial pathogens.
Methods
Chemicals and biological materials
All antibiotics used in this study were obtained from Sigma Aldrich, St. Louis, MO, USA. P. aeruginosa ATCC 27853, K. pneumoniae ATCC 700603, S. flexneri ATCC 9199, S. enterica subsp. enterica serovar Choleraesuis ATCC 10708, S. aureus ATCC 29213, A. baumannii AYE (ATCC BAA-1710), A. baumannii SDF (ATCC BAA-1709), and A. baumannii ATCC 19606 were obtained from American Type Culture Collection, USA. A. baumannii AB5075-UW was obtained from Manoil Laboratory, UW Genome Sciences, University of Washington, USA. M. smegmatis and E. coli MG1655 were obtained from lab collection. The clinical isolates of A. baumannii (nā=ā16, obtained from Government Medical College and Hospital, Chandigarh, India) and E. coli (nā=ā3, obtained from Microbial Culture Repository Division of CIRD, Dr. B. Lal Clinical Laboratory Pvt Ltd, Jaipur, India) (listed in Supplementary TableĀ 5) were minimally passaged and stored at ā80āĀ°C. All strains used in this study were routinely grown at 37āĀ°C in Cation adjusted Mueller Hinton medium (HIMEDIA, India). M. smegmatis was grown in Mueller Hinton broth containing 0.1% Tween 80. Human breast cancer cell line (MCF-7) line was obtained from National Centre for Cell Science, Pune. Dulbeccoās modified Eagle medium (DMEM) and fetal bovine serum (FBS) were obtained from Sigma Aldrich, USA. C. elegans fer-1 nematode and E. coli OP50 was obtained from Dr. Kavita Babu, Department of Biological Science, IISER Mohali, as a kind gift.
Antibiotic susceptibility testing
MIC values of studied antimicrobials were determined with three biological replicates; each biological replicate contains three technical replicates. Assay was performed by broth microdilution method in 96-well polystyrene plate (Flat bottom sterile, Genaxy Scientific, India) with an initial inoculum of 106āCFU/mL in Cation adjusted Mueller Hinton broth (CAMHB) according to CLSI guidelines38. Inoculum was prepared using actively growing mid-logarithmic phase cells. Plates were routinely incubated at 37āĀ°C in a humidity saturated incubator (KĆ¼hner LT-X shaker, Adolf KĆ¼hner AG, Switzerland) to prevent edge effect. Growth was monitored by OD600nm after 18āh of incubation using a Spectramax plus plate reader (Molecular Devices, USA).
Screening of antibioticāantibiotic combinations using checkerboard assay
In this screening, two quinolonesānalidixic acid and ciprofloxacināwere probed in A. baumannii AYE against antibiotics from different classes representing major classes of antibiotics such as ampicillin, fosfomycin, gentamicin, erythromycin, polymyxin B, tetracycline, and rifampicin. Two-dimensional microdilution checkerboard assays were performed in 96-well polystyrene plates (12āĆā8 matrix, starting with 4Ć MIC), to unveil the antibioticāantibiotic interaction effects of two selected antibiotic pairs. To evaluate the interaction of antibiotics, the FIC was calculated for each combination. FIC was calculated using the formula described below.
FICI is defined as the sum of individual FICs. Synergy was defined as an FICI value of ā¤0.5 and additivity or indifference was defined as an FICI value of ā„0.5 to <4, whereas antagonism was defined as an FICI value of ā„439.
In this study, we aimed to identify the antibiotic combination that can rejuvenate activity of either nalidixic acid or ciprofloxacin against A. baumannii AYE.
Time-kill kinetics
The time-kill experiments were performed in CAMHB (HIMEDIA, India) according to the previously described method with a slight modification14. An overnight culture of A. baumannii AYE raised from a single colony was diluted freshly 1ā:ā1000 in 5āml CAMHB and incubated at 37āĀ°C with aeration at 150ār.p.m. for 2āh. After 2āh, cells were diluted 1ā:ā100 in CAMHB containing 1Ć MIC of nalidixic acid alone (512āmg/L), 1Ć MIC of tetracycline alone (64āmg/L), 1Ć FIC (1/8th MIC of both), and 2Ć FIC (1/4th MIC of both) of the combination (here, for A. baumannii AYE, FICI is 0.25). Each tube received an initial bacterial inoculum of ~107āCFU/mL. At indicated time intervals, 100āĀµl aliquots of cultures were removed and washed single time with 1Ć phosphate buffer saline (PBS), and were plated on CAMH agar plates after tenfold serial dilution in 1Ć PBS. Plates were incubated at 37āĀ°C for 18āh. The time-kill curve was plotted using the mean colony count (Log10 CFU/mL) vs. time over 24āh.
Membrane damage assay
Membrane damage assay was performed according to the previously described method with a slight modification40. Briefly, A. baumannii AYE cells were freshly grown till OD600nmā~ā0.4 in CAMH broth and further diluted 1ā:ā1000 in CAMH broth with an addition of nalidixic acid, tetracycline alone (at 1Ć MIC corresponding 512 and 64āmg/L, respectively), or nalidixic acid and tetracycline combination (at 1Ć FIC corresponding 64 and 8āmg/L, respectively). A. baumannii SDF, E. coli RPTU54, and E. coli MG1655 cells were prepared similar to A. baumannii AYE; concentrations of antibiotic used for these bacteria are described in Supplementary Fig.Ā 5. Triton X-100 (at 0.01% vol/vol) was added as a positive control. Cells were incubated for 4āh at 37āĀ°C with shaking at 150ār.p.m. Cells were collected and washed twice in 1Ć PBS, having 0.4% glucose (wt./vol) at room temperature. SYTOXā¢ Orange (Invitrogenā¢, USA) was added to a final concentration of 5āĀµM and incubated for 10āmin at room temperature in the dark. Cells (membrane damage) were analyzed using flow cytometer (BD FACSVerseā¢) with excitation at a wavelength of 547ānm and emission at a wavelength of 570ānm. For each sample, 10,000 events were recorded. Histograms (Half Offset) were analyzed and created using FlowJoā¢ Software for Windows v.10.0.4 (BD Biosciences, USA). SPHEROā¢ Rainbow Calibration Particles (BD Biosciences, USA) were used for instrument calibration.
For membrane damage doseāresponse assay, freshly grown A. baumannii AYE cells (OD600nmā~ā0.4) were washed twice with 1Ć PBS, having 0.4% glucose (wt./vol), and subsequently resuspended in the same buffer at OD600nmā~ā0.3. Next, SYTOXā¢ Orange (Invitrogenā¢, USA) was added to the cells at a final concentration of 5āĀµM at this stage. Then, nalidixic acid was added at different concentrations (0, 16, 32, 64, 128, 256, 512, and 1024āmg/L; 1Ć MIC of nalidixic acid represents 512āmg/L for this strain) in cell suspension and was immediately pipetted into the black polystyrene plates (CorningĀ®, USA) at 100āĀµl/well. The fluorescence reading was monitored (at room temperature) using a SynergyTM H1 Hybrid Multi-Mode fluorescence spectrophotometer (BioTek, USA) at an excitation wavelength of 545ānm and an emission wavelength of 570ānm for 60āmin at every 5āmin. The fluorescence readings were normalized as percentage with respect to 0āmg/L nalidixic acid fluorescence (i.e., 0% membrane damage) and were plotted against log10 concentration of nalidixic acid. Effective concentration (EC50) for membrane damage was plotted using ādose responseāinhibition, variable slope parameterā in GraphPad Prism 7 software (GraphPad, La Jolla, California, USA).
Tetracycline uptake assay
The tetracycline uptake assay was performed according to the previously described method8. The tetracycline uptake assay was monitored by fluorescence enhancement of tetracycline after cellular uptake. Cultures of A. baumannii AYE, A. baumannii SDF, E. coli MG1655, and E. coli RPTU54 were grown to OD600nmā~ā0.6. Cells were pelleted down at 1200āĆāg for 10āmin and resuspended in 10āmM HEPES buffer (pH 7.2) to a final OD600nmā~ā0.5. Tetracycline was added to the cells at a final concentration of 128āmg/L at this stage. Then, nalidixic acid was added at different concentrations (for A. baumannii AYE 1Ć, 2Ć, 4Ć, and 8Ć MIC represents 512, 1024, 2048, and 4096āmg/L, respectively; concentrations of nalidixic acid used for A. baumannii SDF, E. coli MG1655, and E. coli RPTU54 is described in Supplementary Fig.Ā 3) in cell suspension and finally pipetted into the black polystyrene plates (CorningĀ®, USA) at 100āĀµl/well. The fluorescence reading was monitored (at room temperature) using a SynergyTM H1 Hybrid Multi-Mode fluorescence spectrophotometer (BioTek, USA) at an excitation wavelength of 405ānm and an emission wavelength of 535ānm for 60āmin at every 5āmin. The fluorescence readings were normalized with respect to tetracycline fluorescence at time zero and plotted against time.
Fluorescence microscopy and determination of protein per cell
Cultures of A. baumannii AYE, E. coli MG1655, and E. coli RPTU54 were grown till OD600nmā~ā0.2 in fresh CAMH broth. Cells were treated with either nalidixic acid, tetracycline alone, or in combination for 3āh (each antibiotics and their combination were used at 0.75Ć of MIC, for A. baumannii AYE, 384āmg/L of nalidixic acid, or 48āmg/L of tetracycline was used either alone or in combination; for E. coli MG1655, 6āmg/L of nalidixic acid or 0.75āmg/L of tetracycline was used either alone or in combination; for E. coli RPTU54, 768āmg/L of nalidixic acid or 12āmg/L of tetracycline was used either alone or in combination). Cells were washed two times with 1Ć PBS at room temperature. Cells were stained with 4ā²,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher Scientific, USA) at a concentration of 5āĀµg/mL for 5āmin. Cells were mounted on agarose pad (1% wt./vol made in 1Ć PBS) and imaged with a fluorescence microscope equipped with DIC and DAPI filter set (Zeiss AxioScope.A1, Zeiss, Germany). Image processing was done using ZEN lite software. For morphometric analysis, cell lengths were measured manually using ImageJ software (NIH, http://imagej.nih.gov/ij/) for at least 500 cells (from 10 different field of view) in each condition.
To calculate protein per cell, 1āml culture was collected after antibiotic treatment (each antibiotic or its combination were used at a concentration described above), washed in PBS, and lysed using BugBusterĀ® Protein Extraction Reagent (Merck, Germany); total protein concentration was determined using Bradford reagent following the manufacturerās instructions (HIMEDIA, India). Cell number was estimated by colony plate count on CAMH agar. Mean protein per cell was determined after dividing total protein by number of cells for each condition. The experiment was performed with three independent biological replicates.
Synergy in the presence of uncoupling agent CCCP
PMF plays an important role in antibiotic susceptibility and drug interactions17. To check the role of PMF in nalidixic acid and tetracycline susceptibility, as well as their interaction against A. baumannii AYE, two-dimensional checkerboard assays (fixed 12āĆā8 matrix containing nalidixic acid and tetracycline) were performed in 96-well plates with varying concentration (0, 5, 10, 15, 20, and 25āĀµM) of H+ uncoupler carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (Sigma Aldrich, St. Louis, USA)41. CCCP causes the uncoupling of protons across the bacterial membranes and can change antibiotic susceptibility. The plate containing only antibiotics, i.e., nalidixic acid and tetracycline matrix without CCCP, acts as the control for this experiment.
Spectrophotometric measurement of PMF disruption
Antibiotics can disturb PMF directly, which may be responsible for cellular lethality17. We also directly measured the role of nalidixic acid, tetracycline, or their combination on PMF in A. baumannii AYE. PMF was monitored using a potential-sensitive probe, DiBAC4(3) (Invitrogenā¢, USA). The fluorescence of DiBAC4(3) changes in response to fluctuation in membrane potential. A. baumannii AYE cells were grown till OD600nmā~ā0.2 and washed twice in 1Ć PBS containing 0.4% glucose (wt./vol). Cells were pre-incubated with 10āĀµM of DiBAC4(3) for 10āmin42. After 10āmin, cells were treated with either nalidixic acid (at 512āmg/L), tetracycline (at 64āmg/L) alone, or in combination (nalidixic acid and tetracycline at 64 and 8āmg/L, respectively). Immediately after the addition of antibiotics, fluorescence reading was monitored (at 37āĀ°C) using a SynergyTM H1 Hybrid Multi-Mode fluorescence spectrophotometer (BioTek, USA) at an excitation wavelength of 490ānm and an emission wavelength of 516ānm for 60āmin at every minute. Triton X-100 (0.01% vol/vol) acts as positive control for this experiment.
Measurement of ROS using flow cytometry
A fluorescent probeāH2DCF-DA dye (Invitrogenā¢, USA)āwas used to detect the amount of ROS generated upon antibiotic treatment. Briefly, A. baumannii AYE cells were grown till OD600nmā~ā0.5, collected, and washed with 1Ć PBS containing 0.4% glucose (wt./vol). Cells were treated with either nalidixic acid (at 512āmg/L), tetracycline (at 64āmg/L) alone, or in combination (nalidixic acid and tetracycline at 64 and 8āmg/L, respectively) for 4āh. After treatment, cells were collected and centrifuged at 5000ār.p.m. at room temperature. The cells were washed twice with 1Ć PBS and resuspended in 1Ć PBS containing 5āĪ¼M H2DCF-DA dye43. Cells were incubated in the dark at room temperature for 10āmin. After incubation, the cells were washed twice with 500āĪ¼l of 1Ć PBS to remove the excess dye and resuspended in 1Ć PBS for flow cytometry analysis (BD FACSVerseā¢). ROS was analyzed by flow cytometry with excitation at a wavelength of 488ānm and emission at a wavelength of 527ā532ānm. For each sample, 10,000 events were recorded. SPHEROā¢ Rainbow Calibration Particles (BD Biosciences, USA) were used for instrument calibration. Histograms (Half Offset) were analyzed and created using FlowJoā¢ Software for Windows v.10.0.4 (BD Biosciences, USA).
RNA isolation, cDNA synthesis, and quantitative RT-PCR
Quantitative reverse transcription PCR (RT-PCR) was performed according to the previously described method with modification10. Overnight cultures of A. baumannii AYE, E. coli MG1655, and E. coli RPTU54 were diluted 1ā:ā1000 into 5āml CAMH broth and grown at 37āĀ°C to OD600nmā~ā0.3. Cells were treated with either nalidixic acid or tetracycline alone, or their combination at 0.75Ć MIC (for A. baumannii AYE, 384āmg/L of nalidixic acid or 48āmg/L of tetracycline was used either alone or in combination; for E. coli MG1655, 6āmg/L of nalidixic acid or 0.75āmg/L of tetracycline was used either alone or in combination; for E. coli RPTU54, 768āmg/L of nalidixic acid or 12āmg/L of tetracycline was used either alone or in combination) followed by 3āh incubation at 37āĀ°C with shaking at 150ār.p.m. Cells were collected and RNA was extracted using RNAiso Plus (Takara Bio, Inc., Japan). cDNA was prepared for RT-qPCR using First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, USA). Relative gene expression was estimated by RT-qPCR as previously described using PowerUpā¢ SYBRĀ® Green Master Mix, following the manufacturerās instructions (Applied Biosystems, USA)44,45. For A. baumannii groEL, ftsZ, secA, and gmk were used as housekeeping genes. For E. coli groES, ftsZ, secA, and gmk were used as housekeeping genes46. Relative expression of gene of interest (16s rRNA) was normalized with respect to all four housekeeping genes. Primer sequences used in this study are described in Supplementary TableĀ 6. All experiments were conducted in at least three biological replicates.
Measurement of accumulation and efflux kinetics by efflux pump
Ethidium bromide accumulation and efflux assays were carried out as previously described with minor modification47. Ethidium bromide is a common substrate for efflux pumps in bacteria. Cultures of E. coli MG1655 and E. coli RPTU54 were grown to an OD600nmā~ā0.6, washed with PBS, and finally resuspended in PBS to an OD600nmā~ā0.2. For ethidium bromide accumulation assay, cultures were loaded with 20āĀµg/ml of ethidium bromide and 0.4% glucose (wt./vol), and were immediately aliquoted into a black 96-well plate. For the ethidium bromide efflux assay, cultures were preloaded with 20āĀµg/ml of ethidium bromide without glucose and were incubated for 30āmin at room temperature. Cells were washed two times with PBS and finally resuspended in PBS supplemented with 0.4% glucose (wt./vol) (to initiate efflux) to an OD600nmā~ā0.2. Fluorescence was measured using a SynergyTM H1 Hybrid Multi-Mode fluorescence spectrophotometer (BioTek, USA) at an excitation wavelength of 520ānm and an emission wavelength of 590ānm for 60āmin at every 2āmin.
For efflux inhibition assay, cells were preloaded with 20āĀµg/ml of ethidium bromide or 5āĀµg/ml Hoechst 33342 (Thermo Fisher Scientific, USA) without glucose and were incubated for 30āmin at room temperature. Cells were washed and resuspended in PBS to an OD600nmā~ā0.2. Then, nalidixic acid was added at different concentrations (0, 16, 32, 64, and 128āmg/L; 1Ć MIC of nalidixic acid represents 512āmg/L for this strain) in cell suspension and immediately pipetted into the black polystyrene plates (CorningĀ®, USA) at 100āĀµl/well. CCCP (100āĀµM) was used as a positive control for this experiment. The fluorescence reading was monitored as described above. For Hoechst 33342 dye, an excitation wavelength of 360ānm and an emission wavelength of 485ānm was used. The fluorescence readings were normalized as percentage with respect to 0āmg/L nalidixic acid fluorescence and plotted against time.
In vitro cytotoxicity of nalidixic acid and tetracycline combination
Cytotoxicity on human cell line (MCF-7) was performed by fluorescence-based resazurin (Sigma Aldrich, USA) assay as described earlier with minor modification48,49. Cells (1āĆā105) were incubated with nalidixic acid alone (32ā2048āmg/L), tetracycline alone (8ā512āmg/L), or nalidixic acid and tetracycline combination (starting with 32āmg/L of nalidixic acid and 8āmg/L of tetracycline till 2048āmg/L of nalidixic acid and 512āmg/L of tetracycline) in 96-well plates, and cultured in DMEM (Sigma Aldrich, USA) supplemented with 10% heat-inactivated FBS (Sigma Aldrich, USA) at 37āĀ°C for 24āh, followed by resazurin tests. Cells without antibiotic acts as control (0% cytotoxicity) in this experiment.
In vivo efficacy of nalidixic acid and tetracycline combination in C. elegans infection assay
C. elegans is a known pathogenesis model for various human pathogens such as A. baumannii24. A. baumanniiāC. elegans infection assay was performed in a liquid medium as described previously, with slight modifications24. C. elegans fer-1 was routinely maintained on nematode growth medium plates at 16āĀ°C supplemented with E. coli OP50 as a food source. The C. elegans fer-1 strain was used, because it becomes sterile at 25āĀ°C. The infection assay was carried out in 96-well polystyrene plates in a final volume of 200āĀµL. Assay media consisted of 90% M9 buffer (Amresco, Inc., USA) supplemented with 2āmM MgSO4, 100āĀµM CaCl2, 10āĀµM FeCl3, and 10% CAMH broth along with nalidixic acid (512āmg/L), tetracycline (0.5āmg/L), or the combination (1Ć FICānalidixic acid and tetracycline at 128 and 0.125āmg/L, respectively; 2Ć FICānalidixic acid and tetracycline at 256 and 0.25āmg/L, respectively). For infection study, we used opaque colony of A. baumannii AB5075-UW (a highly virulent MDR strain) at 105āCFU/mL (OD600nmā~ā0.01)50. Fifteen to 17 worms (L3 stage) were dispensed in each well manually, using an electronic 12-channel pipette (XplorerĀ® Plus, Eppendorf, Germany) at low dispensing speed to minimize physical injury to worms. One group of larvae was kept uninfected and served as controls for this experiment. Deaths were scored every 24āh during a total incubation period of 120āh using four biological replicates (each replicate contains a minimum of 15 C. elegans, nāāā60 total). Survival curves were plotted using the KaplanāMeier method and differences in survival were calculated using the log-rank test in GraphPad Prism 7 software (GraphPad, La Jolla, California, USA). A p-value of ā¤0.05 was considered to be statistically significant.
Statistics and reproducibility
Results are expressed as the meansāĀ±āSEM. Statistically significant differences were evaluated using appropriate tests as mentioned in the figure legends. In all instances, p-valuesāā¤ā0.05 were considered as significant. Appropriate sample sizes are reported under specific methods and in figure legends. RT-PCR assay was performed with three independent biological replicates. The statistical analyses were performed using GraphPad Prism 7 software (GraphPad, La Jolla, California, USA).
Reporting summary
Further information on research design is available in theĀ Nature Research Reporting Summary linked to this article.
References
WHO. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics (WHO, 2017).
Wong, D. et al. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin. Microbiol. Rev. 30, 409ā447 (2017).
Bush, K. in Topics in Medicinal Chemistry - Antibacterials: Volume I (eds Fisher, J. F., Mobashery, S. & Miller, M. J.) 69ā88 (Springer, 2018).
Bollenbach, T. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. Curr. Opin. Microbiol. 27, 1ā9 (2015).
Chait, R., Craney, A. & Kishony, R. Antibiotic interactions that select against resistance. Nature 446, 668 (2007).
Sullivan, G. J., Delgado, N. N., Maharjan, R. & Cain, A. K. How antibiotics work together: molecular mechanisms behind combination therapy. Curr. Opin. Microbiol. 57, 31ā40 (2020).
Jawetz, E. Antibiotic synergism and antagonism: review of experimental evidence. AMA Arch. Intern. Med. 90, 301ā309 (1952).
Ejim, L. et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7, 348 (2011).
Eliopoulos, G. M. & Eliopoulos, C. T. Antibiotic combinations: should they be tested? Clin. Microbiol. Rev. 1, 139 (1988).
Brochado, A. R. et al. Species-specific activity of antibacterial drug combinations. Nature 559, 259ā263 (2018).
Chandrasekaran, S. et al. Chemogenomics and orthology-based design of antibiotic combination therapies. Mol. Syst. Biol. 12, 872ā872 (2016).
Ocampo, P. S. et al. Antagonism between bacteriostatic and bactericidal antibiotics is prevalent. Antimicrob. Agents Chemother. 58, 4573 (2014).
Dillon, N. et al. Surprising synergy of dual translation inhibition vs. Acinetobacter baumannii and other multidrug-resistant bacterial pathogens. Ebiomedicine 46, 193ā201 (2019).
Sopirala, M. M. et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 54, 4678 (2010).
Hutchings, M. I., Truman, A. W. & Wilkinson, B. Antibiotics: past, present and future. Curr. Opin. Microbiol. 51, 72ā80 (2019).
Shang, D. et al. Synergistic antibacterial activity of designed Trp-containing antibacterial peptides in combination with antibiotics against multidrug-resistant Staphylococcus epidermidis. Front. Microbiol. 10, https://doi.org/10.3389/fmicb.2019.02719 (2019).
Farha, M. A., Verschoor, C. P., Bowdish, D. & Brown, E. D. Collapsing the proton motive force to identify synergistic combinations against Staphylococcus aureus. Chem. Biol. 20, 1168ā1178 (2013).
Griffith, J. M. et al. Experimental evolution of Escherichia coli K-12 in the presence of proton motive force (PMF) uncoupler carbonyl cyanide-chlorophenylhydrazone selects for mutations affecting PMF-driven drug efflux pumps. Appl. Environ. Microbiol. 85, e02792ā02718 (2019).
Kohanski, M. A., Dwyer, D. J., Hayete, B., Lawrence, C. A. & Collins, J. J. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130, 797ā810 (2007).
Dwyer, D. J., Kohanski, M. A., Hayete, B. & Collins, J. J. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol. Syst. Biol. 3, 91 (2007).
Nonejuie, P., Burkart, M., Pogliano, K. & Pogliano, J. Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules. Proc. Natl Acad. Sci. USA 110, 16169 (2013).
Bollenbach, T., Quan, S., Chait, R. & Kishony, R. Nonoptimal microbial response to antibiotics underlies suppressive drug interactions. Cell 139, 707ā718 (2009).
Maeda, M., Shimada, T. & Ishihama, A. Strength and regulation of seven rRNA promoters in Escherichia coli. PLos ONE 10, e0144697 (2016).
Jayamani, E. et al. Insect-derived cecropins display activity against Acinetobacter baumannii in a whole-animal high-throughput Caenorhabditis elegans model. Antimicrob. Agents Chemother. 59, 1728ā1737 (2015).
Liu, Y. et al. Anti-HIV agent azidothymidine decreases Tet(X)-mediated bacterial resistance to tigecycline in Escherichia coli. Commun. Biol. 3, 162 (2020).
Zou, L. et al. Synergistic antibacterial activity of silver with antibiotics correlating with the upregulation of the ROS production. Sci. Rep. 8, 11131 (2018).
LƔzƔr, V. et al. Bacterial evolution of antibiotic hypersensitivity. Mol. Syst. Biol. 9, 700 (2013).
Cokol, M. et al. Systematic exploration of synergistic drug pairs. Mol. Syst. Biol. 7, 544 (2011).
Wood, K. B., Wood, K. C., Nishida, S. & Cluzel, P. Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells. Cell Rep. 6, 1073ā1084 (2014).
Cottarel, G. & Wierzbowski, J. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol. 25, 547ā555 (2007).
Vree, T. B., Wijnands, W. J., Baars, A. M. & Hekster, Y. A. Pharmacokinetics of nalidixic acid in man: hydroxylation and glucuronidation. Pharm. Weekbl. Sci. 10, 193ā199 (1988).
USFDA. NegGram.pdf. NDA 14-214/S-058, 3ā12 (USFDA, 2008).
Musher, D. M., Minuth, J. N., Thorsteinsson, S. B. & Holmes, T. Effectiveness of achievable urinary concentrations of tetracyclines against ātetracycline-resistantā pathogenic bacteria. J. Infect. Dis. 131, S40āS44 (1975).
Gaurav, A., Kothari, A., Omar, B. J. & Pathania, R. Assessment of polymyxin B-doxycycline in combination against Pseudomonas aeruginosa in vitro and in a mouse model of acute pneumonia. Int. J. Antimicrob. Agents 56, 106022 (2020).
Melander, R. J., Zurawski, D. V. & Melander, C. Narrow-spectrum antibacterial agents. Medchemcomm 9, 12ā21 (2018).
Leekha, S., Terrell, C. L. & Edson, R. S. General principles of antimicrobial therapy. Mayo Clin. Proc. 86, 156ā167 (2011).
Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623ā628 (2018).
CLSI. Performance Standards for Antimicrobial Susceptibility Testing (Clinical and Laboratory Standards Institute, 2018).
Odds, F. C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrobial Chemother. 52, 1ā1 (2003).
Menzel, L. P. et al. Potent in vitro and in vivo antifungal activity of a small molecule host defense peptide mimic through a membrane-active mechanism. Sci. Rep. 7, 4353 (2017).
Krulwich, T. A., Sachs, G. & Padan, E. Molecular aspects of bacterial pH sensing and homeostasis. Nat. Rev. Microbiol. 9, 330ā343 (2011).
te Winkel, J. D., Gray, D. A., Seistrup, K. H., Hamoen, L. W. & Strahl, H. Analysis of antimicrobial-triggered membrane depolarization using voltage sensitive dyes. Front. Cell Dev. Biol. 4, 29 (2016).
Eruslanov, E. & Kusmartsev, S. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol. Biol. 594, 57ā72 (2010).
Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).
Pfaffl, M. W. & Bustin, S. in AZ of Quantitative PCR 87ā120 (International Univ. Line, 2004).
Rocha, D. J. P., Santos, C. S. & Pacheco, L. G. C. Bacterial reference genes for gene expression studies by RT-qPCR: survey and analysis. Antonie Van Leeuwenhoek 108, 685ā693 (2015).
Wang-Kan, X. et al. Lack of AcrB efflux function confers loss of virulence on Salmonella enterica Serovar Typhimurium. Mbio 8, e00968ā00917 (2017).
Oābrien, J., Wilson, I., Orton, T. & Pognan, F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 267, 5421ā5426 (2000).
Liu, Y. et al. Metformin restores tetracyclines susceptibility against multidrug resistant bacteria. Adv. Sci. 7, 1902227 (2020).
Jacobs, A. C. et al. AB5075, a highly virulent isolate of Acinetobacter baumannii as a model strain for the evaluation of pathogenesis and antimicrobial treatments. Mbio 5, e01076ā01014 (2014).
Acknowledgements
We are grateful to Dr. Kavita Babu, Centre for Neurosciences, IISc Bangalore, for sharing C. elegans fer-1 nematode and E. coli OP50 with us. We thank Shahnawaz Ahmed Baba and Shubham Jain for help with flow cytometry experiments. We also acknowledge the flow cytometry facility available at the Department of Biotechnology, IIT Roorkee. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The PhD fellowship was supported by the Ministry of Human Resource Development (MHRD), Government of India, to A.G.
Author information
Authors and Affiliations
Contributions
A.G. and R.P. designed the study. A.G. conducted the experiments and analyzed the experimental data. V.G. and S.K.S provided clinical strains. R.P. supervised overall study. A.G. drafted the manuscript, with critical revisions from R.P., V.G., and S.K.S. All the authors have approved the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisherās note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the articleās Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the articleās Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gaurav, A., Gupta, V., Shrivastava, S.K. et al. Mechanistic insights into synergy between nalidixic acid and tetracycline against clinical isolates of Acinetobacter baumannii and Escherichia coli. Commun Biol 4, 542 (2021). https://doi.org/10.1038/s42003-021-02074-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s42003-021-02074-5
This article is cited by
-
Metformin reverse minocycline to inhibit minocycline-resistant Acinetobacter baumannii by destroy the outer membrane and enhance membrane potential in vitro
BMC Microbiology (2022)
-
Insights into the antimicrobial effects of ceritinib against Staphylococcus aureus in vitro and in vivo by cell membrane disruption
AMB Express (2022)
-
An optimized antimicrobial peptide analog acts as an antibiotic adjuvant to reverse methicillin-resistant Staphylococcus aureus
npj Science of Food (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.